Pharmaceutical firm Novo Nordisk’s sales growth has accelarated since 2019, when it introduced new financial targets and ambitions for 2025. A theme of the company’s capital markets day, which is taking place at the time of writing on Thursday, is how to continue on this track.
”We are very encouraged by the growth momentum we have now. Today, we will try to explain how we believe we can maintain that growth and how we can drive growth within diabetes and obesity (two of Novo’s business areas, ed.) by maximizing semaglutide’s potential in the short and medium term,” says Novo Nordisk CEO Lars Fruergaard Jørgensen at the meeting.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
Quality System Manager 
SAP System Specialist (Product Supply) – Business Application Services 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Clinical Project Manager 
Account Manager 
Analytical Senior Scientist 
IRT Manager, Clinical Drug Supply 
Strategic Procurement Manager, Direct Spend (Category Manager) 
Director Global Engineering 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Senior Project Manager (GMP - Life Science) 
Director for innovative pre-clinical testing unit 
Production Director 
Nordic Medical Affairs Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Clinical Trial Manager for development of in vitro diagnostics 
(Senior) Drug Substance Specialist 
2 Sales Representatives and Product Specialists